What you should know:
1. MacuLogix provides instruments, tools and education to treat age-related macular degeneration patients.
2. Vivo Capital led the series D round, with contributions from four other firms.
3. MacuLogix raised a $51 million in venture funding and $10 million in venture debt.
4. “With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company’s vision to eliminate blindness caused by AMD,” said MacuLogix CEO and President William D. McPhee.
More articles on leadership:
How total joints propelled an Ohio-based ASC’s strategy for growth and a bigger location
Fox Valley Orthopedics’ Dr. Vishal Mehta on total joint replacement
Orthopedic trauma, spine & more: 3 trends, growth areas for ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.